Challenges and changes in the Polish healthcare system

Society and Economy

Volumn 33, Issue 3, 2011, Pages 575-594

  Orlewska, Ewa ^a,b  

^a Centre for Pharmacoeconomics   (Poland)

^b Operációkutatás és Aktuáriustudományok Tanszék docense   (Hungary)

Author keywords

healthcare system; I18; pharmaceutical policy; Poland; reform

Indexed keywords

EID: 84855704199     PISSN: 15889726     EISSN: 1588970X     Source Type: Journal    
DOI: 10.1556/SocEc.33.2011.3.8     Document Type: Article

References (34)

1. Boncz, I.-Brodszky, V.-Péntek, M.-Ágoston, I.-Nagy, Z.-Kárpáti, K.-Kriszbacher, I.-Fuszek, P.-Gulácsi, L. (2009): The Disease Burden of Colorectal Cancer in Hungary. "European Journal of Health Economics" 10(1): S35-S40.
2. Brodszky, V.-Péntek, M.-Gulácsi, L. (2008a): Efficacy of Adalimumab, Etanercept and Infliximab Based on ACR50 Response in Psoriatic Arthritis after 24 Weeks Treatment. "Scandinavian Journal of Rheumatology" 37: 399-400.
3. Brodszky, V.-Nagy, V.-Farsang, C.-Kárpáti, K.-Gulácsi, L. (2008b): The Efficacy of Indapamide in Different Cardiovascular Outcomes; Meta-analysis. "Orvosi Hetilap (Hungarian Medical Journal)" 2(2): 181-191.
4. Brodszky, V.-Orlewska, E.-Péntek M.-Kárpáti, K.-Skoupá, J.-Gulácsi, L. (2010a): Challenges in Economic Evaluation of New Drugs: Experience with Rituximab in Hungary. "Medical Science Monitor" 16(1): SR1-5.
5. Brodszky, V.-Bálint, P.-Géher, P.-Hodinka, L.-Horváth, G.-Koó, É.-Péntek, M.-Polgár, A.-Seszták, M.-Szántó, S.-Ujfalussy, I.-Gulácsi, L. (2009): Disease Burden of Psoriatic Arthritis Compared to Rheumatoid Arthritis, Hungarian Experiment. "Rheumatology International" 30(2): 199-205.
6. Brodszky, V.-Péntek, M.-Bálint, P. V.-Géher, P.-Hajdú, O.-Hodinka, L.-Horváth, G.-Koó, E.-Polgár, A.-Seszták, M.-Szántó, S.-Ujfalussy, I.-Gulácsi, L. (2010b): Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire, the Functional Status (HAQ) and the Utility (EQ-5D) Measures in Psoriatic Arthritis; Results from a Cross-sectional Survey. "Scandinavian Journal of Rheumatology" 39(4): 303-309.
7. Draft of Reimbursement Act (2010): Draft Act on the Reimbursement of Drugs, Food Products for Special Dietary Purposes and Medical Devices with Public Funds, submitted for public consultations on 9 September 2010. (2010) Food Products for Special Dietary Purposes and Medical Devices with Public Funds
8. Érsek, K.-Kovács, T.-Wimo, A.-Kárpáti, K.-Brodszky, V.-Péntek, M.-Jönsson, L.-Gustavsson, A.-McDaid, D.-Kenigsberg, P. A.-Valtonen, H.-Gulácsi, L. (2010): Costs of Dementia in Hungary, "Journal of Nutrition, Health and Aging" 14(8): 633-639.
9. Gulácsi, L. (2007): The Time for Cost-effectiveness in the New European Union Member States: The Development and Role of Health Economics and Technology Assessment in the Mirror of the Hungarian Experience. "European Journal of Health Economics" 8(2): 83-88. (Pubitemid 46742899)
10. Gulácsi, L. (2010): Future Challenges for Health Economics and Technology Assessment of Biological Drugs. "European Journal of Health Economics" 11(3): 235-238.
11. Gulácsi, L.-Boncz, I.-Drummond, M. (2004): Issues for Countries Considering Introducing the 'fourth Hurdle'. The Case of Hungary. "International Journal of Technology Assessment in Health Care" 20(3): 337-341. (Pubitemid 39079569)
12. Gulácsi, L.-Vas, G.-Pintér, I.-Kriszbacher, I. (2009b): Colorectal Cancer Screening Policy in Hungary. "International Journal of Technology Assessment in Health Care" 25(1): 109-110.
13. Gulácsi, L.-Brodszky, V.-Péntek, M.-Varga, S.-Vas, G.-Boncz, I. (2009a): History of Health Technology Assessment in Hungary. "International Journal of Technology Assessment in Health Care" 25Suppl 1: 120-126.
14. GUS (2010): "National Health Account 2008". Central Statistical Office. http://www.stat.gov.pl/cps/rde/xbcr/ gus/PUBL-zos-narodowy-rachunek-zdrowia-2008.pdf
15. Health Barometer Report (2010): Polish Health care at bottom of pile. "Warsaw Business Journal" 6 Oct 2010. http: //www.wbj.pl/article-51468-polish-health-care-at-bottom-of-pile.htmltyp=ise
16. Makai, P.-Wagner, C.-Klazinga, N.-Boncz, I.-Gulácsi, L. (2008): Quality Management and Patient Safety; Survey Results from 102 Hungarian Hospitals. "Health Policy" 90(2-3) 175-180.
17. Minier, T.-Péntek, M.-Brodszky, V.-Ecseki, A.- Kárpáti, K.-Polgár, A.-Czirják, L.-Gulácsi, L. (2009): Cost-of-illness of Patients with Systemic Sclerosis, "Rheumatology" 49(10): 1920-1928.
18. Öesterle, A.-Gulácsi, L. (2007): Das Gesundheitssystem in Ungarn: Entwicklungen, Herausforderungen und Reformen, "Soziale Sicherheit" Sept. 418-429.
19. Öesterle, A.-Gulácsi, L.-Pechová, M. (2007): Gesundheitssytementwicklung in den MOE-Landern: Zwischen socialen Rechen and Marktallokation. "Kurswechsel" 2: 18-27.
20. Orlewska, E. (2002): The Cost-effectiveness of Alternative Therapeutic Strategies for Management of Chronic Hepatitis B in Poland. "Value in Health" 5(5): 404-420.
21. Orlewska, E.-Gulácsi, L. (2009). Budget-impact Analyses: A Critical Review of Published Studies. "PharmacoEconomics" 27(10): 807-827.
22. Orlewska, E.-Mierzejewski, P. (2004): Polish Guidelines for Conducting Financial Analysis-proposal. "Value in Health" 7(1): 1-10.
23. Orlewska, E.-Budaj, A.-Tereszkowski-Kamimski, D. (2003): Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in acute coronary syndrome patients in Poland. "Pharmacoeconomics" 21(10): 737-748. (Pubitemid 36920638)
24. Orlewska, E.-Zammit, D.-Yong, Yuan-Kutikova, L.-Berak, H.-Halota, W.-Hay, J. W. (2008): The Cost-effectiveness Analysis of Entecavir in the Treatment of Chronic Hepatitis B (CHB) in Poland. "Experimental & Clinical Hepatology" 4(3-4): 20-28.
25. Orlewska, E.-Mierzejewski, P-Zaborski, J.-Kruszewska, J.-Wicha, W.-Fryze, W.-Drozdowski, W.-Skibicka, I.-Mirowska-Guzel, D-Czlonkowski, A.-Czlonkowska, A. (2005): Cost of multiple sclerosis in Poland. "European Journal of Neurology" 12: 31-39.
26. Orlewska, E.-Ancuta, I.-Anic, B.-Codrenau, C.-Damjanov, N.-Djukic, P.-Ionescu, R.-Marinchev, L.-Nasonov, E. L.-Peets, T.-Praprotnik, S.-Rashkov, R.-Skoupa, J.-Tlustochowicz, W.-Tlustochowicz, M.-Tomsic, M.-Veldi, T.-Vojinovic, J.-Wiland, P. (2011): Access to Biologic Treatment in Rheumatoid Arthritis (RA) in Central and Eastern European (CEE) Countries. "Medical Science Monitor" 17(4): SR1-13.
27. Péntek, M.-Brodszky, V.-Tóth, E.-Gulacsi, L. (2007a): Characteristics of Patients with Rheumatoid Arthritis in Hungary: Comparison with the QUEST-RA Study. "Annals of Rheumatic Diseases" 66: 1491-1496.
28. Péntek, M.-Horváth, C.-Boncz, I.-Falusi, Z.-Tóth, E.-Sebestyén, E.-Majer, I.-Brodszky, V.-Gulácsi, L. (2008): Epidemiology of Osteoporosis Related Fractures in Hungary from the Nationwide Health Insurance Database, 1999-2003. "Osteoporosis International" 19: 243-249.
29. Péntek, M.-Kobelt, M.-Czirják, L.-Szekanecz, Z.-Poór, G.-Rojkovich, B.-Polgár, A.-Genti, G.-György Kiss, C.-Brodszky, V.-Májer, I.-Gulácsi, L. (2007b): Costs of Rheumatoid Arthritis in Hungary. "Journal of Rheumatology" 34:1437-1439. (Pubitemid 46898132)
30. Poland Pharmaceuticals and Healthcare Report (2010): Poland Pharmaceuticals and Healthcare Report Q1 2011. "Business Monitor International", http://www.companiesandmarkets.com/Market-Report/ poland-pharmaceuticals-and-healthcare-report-q1-2011-405108.asp
31. Pricing Law (2001): Pricing Law of 5th July 2001. "Journal of Acts" 97/2001.
32. Redekop, K.-Orlewska, E.-Maciejewski, P.-Rutten, F.-Niessen, L. (2008): Cost and Effects of Secondary Prevention with Peridnopril in Stable Coronary Heart Disease in Poland. An Analysis of the Europa Study Including 1251 PolisPh atients. "Pharmacoeconomics" 26(10): 861-877.
33. WHO (2008): "European Health for All Database (HFA-DB)". http://www.euro.who.int/en/ what-we-do/data-and-evidence/databases/european-health-for-all-database-hfa- db2
34. Wimo, A.-Jönsson, L.-Gustavsson, A.-McDaid, D.-Ersek, K.-Georges, J.-Gulácsi, L.-Karpati, K.-Kenigsberg, P.-Valtonen, H. (2010): The Economic Impact of Dementia in Europe in 2008-Cost Estimates from the Eurocode Project. "International Journal of Geriatric Psychiatry", forthcoming.